Welcome to our dedicated page for Can-Fite BioPharma news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma stock.
Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Can-Fite BioPharma (NYSE American: CANF) announced IRB approval from Rabin Medical Center for a Phase IIa study on Namodenoson for pancreatic cancer treatment. The open-label trial will enroll around 20 patients whose disease has advanced despite first-line treatment. The study will evaluate safety and clinical activity, with patients receiving 25 mg of Namodenoson twice daily. Previous studies showed promising results, encouraging this new trial. The study protocol CF102-222PC has been submitted to the Ministry of Health. Key endpoints include safety, Objective Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS).
Can-Fite BioPharma has provided an update on the pivotal Phase 3 study for Namodenoson, its lead drug candidate for advanced liver cancer. The study involves 31 medical centers across Europe, Israel, and the US, with Namodenoson holding Orphan Drug and Fast Track status from the FDA.
The compassionate use program is ongoing in Israel and Romania. Previous Phase 2 results showed that Namodenoson prolonged survival and improved quality of life in patients, with some achieving long-term complete responses.
The Phase 3 LIVERATION trial will enroll 450 patients with advanced liver cancer and Child Pugh B7 cirrhosis, comparing Namodenoson to a placebo. The trial's primary endpoint is overall survival, with interim analysis by an Independent Data Monitoring Committee after 50% enrollment.
Liver cancer causes over 700,000 deaths annually, with the HCC treatment market projected to reach $3.8 billion by 2027.
Can-Fite BioPharma announced that the International Journal of Molecular Sciences published a review highlighting the positive effects of its drugs, piclidenoson and namodenoson, on heart diseases. The review, based on over 50 publications, showed that these drugs improved outcomes in pre-clinical studies, such as reducing infarct size and protecting against ischemic injury. Dr. Pnina Fishman noted the drugs' cardio-protective potential and their good safety profile observed in over 1600 patients. Can-Fite is also advancing clinical studies in psoriasis, liver cancer, MASH, and pancreatic cancer.
Can-Fite BioPharma announced that its VP of Business Development, Dr. Sari Fishman, will engage in 23 partnering meetings at the Bio International Convention 2024 in San Diego from June 3-6. These meetings aim to explore potential collaborations with biotech and pharma companies. Can-Fite has existing out-licensing and distribution agreements with seven pharma companies across North America, Europe, and Asia. The company is currently developing two small molecule drugs: Piclidenoson for psoriasis (Phase 3) and Namodenoson for advanced liver cancer (Phase 3), pancreatic cancer (Phase 2a), and NASH (Phase 2b).
Can-Fite BioPharma (NYSE American: CANF; TASE: CANF), a biotechnology firm focused on small molecule drugs for oncological and inflammatory diseases, invites investors to a webinar on June 6, 2024, at 4:15 p.m. ET.
Hosted by RedChip Companies, the event will feature CEO Motti Farbstein and Executive Chairperson/Chief Scientific Officer Pnina Fishman, PhD. They will discuss the company's current development pipeline and upcoming milestones.
Investors can register for the free webinar and pre-submit questions at the provided link.
Can-Fite BioPharma held a conference for 75 oncologists and coordinators to accelerate patient enrollment for the pivotal Phase 3 advanced liver cancer study. The study aims to evaluate Namodenoson as a 2nd or 3rd line treatment for CPB7 patients with HCC. The drug has Orphan Drug status and Fast Track Status with the FDA for HCC treatment. The market for HCC treatments is projected to reach $6.1 billion by 2027.
RedChip Companies will air interviews with Can-Fite BioPharma (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, discusses the company's advanced clinical stage drug development focusing on oncology and inflammatory diseases. Can-Fite has two drug candidates in advanced stages of development with registration plans agreed with the U.S. FDA and the EMA. Gareth Sheridan, Founder and CEO of Nutriband, talks about their AVERSA™ abuse-deterrent transdermal technology to address the global opioid crisis. Nutriband's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million.
Can-Fite BioPharma has received FDA clearance for its small molecule drug, Namodenoson, to treat MASH patients in a Phase IIb study. The drug targets the A3 adenosine receptor in liver cells, showing promise in reducing hepatic steatosis, inflammation, and fibrosis. The Phase IIb trial aims to evaluate Namodenoson's efficacy in 140 MASH patients, with enrollment now open in the US.
Can-Fite BioPharma (NYSE American: CANF) received a Notice of Allowance from the European Patent Office for its patent application related to the use of the CF602 drug candidate for the treatment of erectile dysfunction in patients such as diabetics. The patent has already been issued in other major markets. Can-Fite's CF602 showed promising results in a diabetic rat model, offering an alternative for non-responders to current ED drugs. The company sees this as a significant addition to their IP estate, positioning CF602 as a potential treatment for sexual dysfunction.
Summary not available.